Cases of onychomycosis caused by non-dermatophyte filamentous fungi have increased over the years. It is worth noting that this group of fungi is resistant to fluconazole, thus the importance of determining the in vitro susceptibility patterns to the antifungals available. We determined the minimal inhibitory concentration of amorolfine, ciclopirox, itraconazole and terbinafine using the microdilution method M38-A, as described by the Clinical Laboratory and Standards Institute, of 13 isolates of Aspergillus versicolor obtained from onychomycosis. The final concentrations were: 0.13-64 μg/mL for amorolfine and terbinafine, 0.06 -32 μg/mL for ciclopirox and 0.03-16 μg/mL for itraconazole. Also, we determined the interaction of these drugs by the checkerboard method.The MIC 50 and MIC 90 were ≥ 64.00 and ≥ 64.00 µg/mL for amorolfine, 4.00 and 8.00 µg/mL for ciclopirox, 1.00 and 1.80 µg/mL for itraconazole and 0.50 and 1.36 µg/mL for terbinafine, respectively. Regarding the combination of antifungals, 15.38% of the combinations of ciclopirox-itraconazole presented synergism, while the rest of the combinations showed no interaction. Thus, in vitro susceptibility testing indicates that terbinafine exhibited the highest antifungal activity and amorolfine the lowest against A.versicolor. Also, combining treatments enhances the activity of the drugs, proving a possible alternative for successful treatment of onychomycosis caused by this fungus.